Autologous bone marrow grafts in dogs treated with lethal doses of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.

Abstract

Hematological and immunosuppressive effects of various single doses of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) were evaluated in the preclinical canine model. Immune function appeared not to be impaired by treatment with CCNU, but severe myelotoxicity contributed to the death of 3 of 4 dogs given 10 mg CCNU per kg and 5 of 5 dogs given 15 mg CCNU per kg within 10 days after drug administration. Infusions of autologous bone marrow protected 6 of 6 dogs receiving 15 mg CCNU per kg and 6 of 6 dogs receiving 20 mg CCNU per kg from lethal marrow failure. Dogs given 30 mg CCNU per kg and autologous marrow died within 7 days from severe gastrointestinal toxicity. We conclude that autologous bone marrow support may allow the use of high-dose CCNU regimens and thereby increase its therapeutic efficacy in the treatment of advanced cancer.

• Authors: J Abb, B Netzel, H V Rodt, S Thierfelder
• Journal: Cancer research (Cancer Res) Vol. 38 Issue 7 Pg. 2157-9 (Jul 1978) ISSN: 0008-5472 [Print] United States
• PMID: 350384 (Publication Type: Journal Article)

Chemical References

• BCG Vaccine
• Nitrosourea Compounds
• Lomustine

Topics

• Animals
• BCG Vaccine
• Bone Marrow (drug effects)
• Bone Marrow Transplantation
• Dogs
• Erythrocytes (immunology)
• Immunity, Cellular (drug effects)
• Lomustine (administration & dosage, toxicity)
• Mycobacterium bovis (immunology)
• Nitrosourea Compounds (toxicity)
• Skin Tests
• Time Factors
• Transplantation, Autologous